ch

FDA Aug. 21 unveiled a major new initiative to revise the agency's current good manufacturing practices program for human and animal drugs, including human biological products. FDA plans to focus its regulatory attention on high-risk areas, provide more flexibility to avoid impeding innovation, and make the cGMP program more consistent across the centers.



/index.php?option=com_iwpfile&file=/dir_01/he2002_2221.pdf


/index.php?option=com_iwpfile&file=/dir_01/he2002_2220.pdf


/index.php?option=com_iwpfile&file=/dir_01/he2002_2219.pdf


ll

Concerned Women of America (CWA) issued a petition to FDA highlighting what it views as the agency's many faults in its approval process of RU-486, the abortion pill, and called for the ban of the drug for "severely harming American women." CWA Press Release CWA Petition CWA Petition Bibliography



/index.php?option=com_iwpfile&file=/dir_01/he2002_2222.pdf


/index.php?option=com_iwpfile&file=/dir_01/he2002_2217.pdf


/index.php?option=com_iwpfile&file=/dir_01/he2002_2216.pdf


/index.php?option=com_iwpfile&file=/dir_01/he2002_2215.pdf


ts

Thomas A. Scully

Administrator

Centers for Medicare & Medicaid Services

Humphrey Building

200 Independence Avenue, SW

Washington, DC 20201

Re: Availability in Washington, DC of public comments on proposed rules

Dear Mr. Scully:



Pages

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.